Kornimate/medical-research-clean huggingface dataset:
dexmedetomidine for improved pain relief and recovery in spine surgery

Conditions: Pain, Postoperative

Summary: chronic low back pain (clbp) is a prevalent condition causing significant pain, disability, and reduced quality of life. while various treatments like exercise, nsaids, and spinal manipulation are recommended, their effectiveness is limited. epidural steroid injections can provide short-term relief but may not be cost-effective and have associated risks. dexmedetomidine (dxm) is a selective α2-adrenergic agonist with analgesic properties. it has been used as an adjuvant to anesthetics and analgesics to enhance pain relief and reduce opioid consumption. using dxm in conjunction with local anesthetics for regional blocks has shown promising results in improving analgesia and functional outcomes.


Eligibility criteria:
inclusion criteria: * patients who had chronic lower back pain defined as persistent pain for more than 6 weeks with manifest affection of daily activities; * patients who had chronic lower back pain defined as persistent pain for more than 6 weeks with manifest affection of quality of walking and life; * patients who had chronic lower back pain defined as persistent pain for more than 6 weeks maintained on systemic analgesics; * patients who were free of exclusion criteria were enrolled in the study. exclusion criteria: * the presence of osteolytic vertebral lesions; * the presence of previous surgical intervention; * the presence of allergy to the studied drugs; * patients of asa grade \>ii.
efficacy and safety of bromfenac ophthalmic solution in cataract surgery

Conditions: Cataract

Summary: efficacy and safety of bromfenac ophthalmic solution in cataract surgery


Eligibility criteria:
inclusion criteria: * scheduled for cataract surgery exclusion criteria: * known hypersensitivity to bromfenac and salicylates

Keywords: cataract extraction with intraocular lens implantation
therapeutic drug monitoring to optimize antiretroviral regimens in hiv-infected women who want to breastfeed

Conditions: HIV-1-infection

Summary: this is a prospective, multi-center, longitudinal, mother-infant pair, therapeutic drug monitoring study. the aim of this study is to determine concentrations of antiretroviral drugs in plasma and breastmilk in people living with hiv who chose to breastfeed while using antiretrovirals. at a planned hospital visit an extra maternal blood sample (1 to 2 per visit) and extra infant blood sample (1 per visit) will be collected, as well as a breastmilk sample (1 to 2 per visit). ideally, sample collection will take place at least during the 1, 3 and 6 month post partum follow up visit. measured concentrations will be used to calculate milk to plasma ratios, relative and absolute infant dosages.


Eligibility criteria:
inclusion criteria * patients of at least 18 years of age at the moment of screening * patients with hiv-1 as documented with positive hiv antibody test, hiv rna of antigen test * patients breastfeeding their infant * patients using antiretrovirals for the treatment of hiv-1 with a marketing authorisation in europe (table 1 in appendix) * patients using current antiretrovirals for a minimum of 2 weeks to assure drug concentrations are in steady state * patients who are able and willing to sign an informed consent exclusion criteria: no exclusion criteria will be used at the screening for the trial.

Keywords: breastfeeding therapeutic drug monitoring breast milk to maternal plasma ratio antiretroviral therapy
suction drain versus the use of adaptive skin sutures after mastectomy ± axillary lymphadenectomy; a prospective randomised study

Conditions: in Situ Breast Cancer; Invasive Breast Cancer

Summary: the objective of this prospective randomized study is to perform qualitative and quantitative comparisons between the insertion of traditional suction drains (arm: suction drain) versus the application of absorbable adaptive sutures (arm: adaptive suture) following simplex mastectomy or modified radical mastectomy in the light of the total volume of withdrawn serum from wound cavity, the extent of early postoperative analgesic requirements and quality of life.


Eligibility criteria:
inclusion criteria: * female patients with primary unilateral, stage 0, i or ii, t3n1m0 breast cancer necessitating simple or modified radical mastectomy exclusion criteria: * age above 75 years and bad general state * pregnancy * autoimmune disease * non-radical excision * mastitis carcinomatosis * lymphangitis carcinomatosis * wound infection necessitating treatment

Keywords: simple mastectomy modified radical mastectomy wound care suction drain adaptive suture
univation xm france

Conditions: Osteoarthritis, Knee; Osteoarthrosis of Knee; Arthritis Knee; Unicompartmental Knee Arthroplasty

Summary: the study is set up due to regulatory purposes and to collect routine clinical data of the mobile-bearing implant univation xm. the study is designed as a prospective follow-up study with a historic patient cohort who have been treated with the product under investigation two years ago. this design is selected to quicker realize follow-up data as patients have already been treated in the past. as the mobile version of the implant is not widely used, the study will be set up as a monocentric study in france. the clinical hypothesis of the study is that patients who are treated with the product under investigation have a similar outcome and survival rate in comparison to other established unicondylar knee systems on the market. comparison for the later evaluation will be taken out of recent orthopaedic registries.


Eligibility criteria:
inclusion criteria: * patient has received a primary mobile bearing uka at the study site between january 2017 and december 2018 using the product under investigation * patient's written consent and willingness to participate at the clinical study and the follow-up examinations exclusion criteria: * pregnancy * patient age \<18 years at the time of the surgery

Keywords: unicompartmental knee arthroplasty retrospective study knee society score
pet/ct imaging of angiogenesis in patients with neuroendocrine tumors using 68ga-nodaga-e[c(rgdyk)]2

Conditions: Neuroendocrine Tumors

Summary: the aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis pet/ct with the radioligand 68ga-nodaga- e\[c(rgdyk)\]2 in patients with neuroendocrine tumors (nets).

the radioligand 68ga-nodaga- e\[c(rgdyk)\]2 targets the arg-gly-asp (rgd) sequence known to bind with the αvβ3 integrin that is expressed on the surface of angiogenic blood vessels or tumor cells. the radioligand can be used to visualize tumor angiogenesis using pet/ct. a total of 120 net patients will be subjected to an angiogenesis-pet/ct scan. follow-up will be performed (from the time of the angiogenesis pet/ct) at 6 months for disease specific survival (dss) and a 1 year follow-up for pfs and os. the uptake of 68ga-nodaga-e\[c(rgdyk)\]2 (standardized uptake values, suvmax) in tumor lesions will be quantified as standardized uptake values (suvmax/suvmean) and compared with pfs, dss and os (dichotomized above/below median suvmax and analyzed by kaplan-meier).

Eligibility criteria:
inclusion criteria: * diagnosed with gastro-entero-pancreatic neuroendocrine tumors (gep-net; grade: g1-g3) or broncho-pulmonary net. * who performance status 0-2 * must be able to read and understand the patient information in danish and to give informed consent exclusion criteria: * pregnancy * breast-feeding * weight more than the maximum weight limit for the pet/ct bed of the scanner (140 kg) * history of allergic reaction attributable to compounds of similar chemical or biologic composition to 68ga-nodaga-e\[c(rgdyk)\]2 * in case of broncho-pulmonary net, the subtype must not be small cell lung cancer (sclc)

Keywords: 68ga-nodaga-e[c(rgdyk)]2 angiogenesis pet/ct neuroendocrine tumors
autologous bone marrow transplantation in acute non-lymphoblastic leukemia during first or subsequent remission

Conditions: Leukemia, Myelocytic, Acute; Leukemia; Blood and Marrow Transplant (BMT)

Summary: evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for aml.

to use high dose chemotherapy with autologous stem cell rescue to try to increase the chance of long term control and cure of the disease.

Eligibility criteria:
inclusion criteria:- must be in remission * adequate organ function exclusion criteria:- prior mds * active infection * liver disease
measurement properties in people with hemophilia

Conditions: Hemophilia a; Hemophilia B; Musculoskeletal Complication; Measurement Error

Summary: the aim of this project is to determine the measurement properties (namely reliability and validity) of a set of clinical assessments, measuring different aspects of physical function.

the medical treatment of hemophilia has advanced greatly in recent years. there are now medications that reduce the physical symptoms of hemophilia. nevertheless, those affected by hemophilia suffer from restricted mobility, reduced strength, reduced balance and pain as a result of the repeated bleeding. in order to make well-founded decisions regarding possible supportive therapeutic or medical measures, it is important to be able to estimate the extent of such limitations and whether these will change or remain stable. the study is needed to validate the measurement properties of measurement instruments used to measure the effects of physical training interventions in participants with hemophilia. clinical questions can only be solved if measuring instruments with sufficient measuring properties are used. these measurement properties must be evaluated in a relevant population. otherwise, health professionals cannot assess whether measures or treatment are not effective or whether measured changes are not large enough to detect an actual change. therefore, research is required to ensure that adequately studied measurement instruments are available for clinical assessment of those affected by adult participants with hemophilia. some of the tests (such as the unipedal stance test or four square step test) have already been studied in children with hemophilia or in participants with other diseases. since hemophilia is a disease with specific effects, the measuring instruments must also be researched in this participant group. there is still a research gap that the investigators would like to close with this study. for the study, the investigators selected tests that are already being used on adult participants with hemophilia and have had good experiences in practice. the tests are safe and can be carried out with little strain.

Eligibility criteria:
inclusion criteria: * diagnosed hemophilia types a or b * adult people ≥ 18 years * patients on prophylactic factor or non-factor replacement treatment, or on demand factor replacement treatment. * able to walk for 20 meters independently, with or without walking aid * signed informed consent to participate in the study exclusion criteria: * severe health conditions like severe cardiovascular, pulmonary, neurological or musculoskeletal diseases. * unable to perform the assessments due to disability or language problems.
the effect of therapeutic ultrasound on soft tissue: an experimentally-induced skin model

Conditions: Inflammation

Summary: the purposes of study are to investigate the effect of therapeutic ultrasound for the inflammatory skin repair and whether the tissue repair under ultrasound treament is depend on different inflammatory level.

therapeutic ultrasound for soft tissue repair has been used in clinical during the past decades. in some recent systematic review, the evidence of clinical trials were insufficiency. we assumed the reaserch biasin clinical trials may be due to the different inflammatory level of soft tissue under the similar ultrasound intensity. our purpose of study is to investigate the effect of therapeutic ultrasound for the inflammatory skin repair and whether the tissue repair under ultrasound treament is depend on different inflammatory level.

Eligibility criteria:
inclusion criteria: 1. asia healthy subjects 2. aged 20-45 years exclusion criteria: 1. disadvantaged groups 2. systemic disease, such as dm, cancer, autoimmune disorder 3. hyperhidrosis or hypothyroidism 4. a past history of dermatitis 5. active infective or inflammatory cutaneous disease 6. smoking or drinking 7. take medicine, over sun exposure, exercise or menstruation during experimental period 8. contraindication of therapeutic ultrasound

Keywords: sodium lauryl sulfate skin irritants inflammation therapeutic ultrasound
first-line antibiotic therapy for early-stage hp(+) gastric pure dlbcl

Conditions: Gastric Diffuse Large B-cell Lymphoma

Summary: aims: a nationwide study to prospectively validate 1. the complete histological and molecular remission rate for antibiotics as 1st-line therapy for early-stage hp-positive gastric pure (de novo) dlbcl 2. the durability of complete histological remission after antibiotics 3. the usefulness of pattern of nf-kb, bcl10, baff, and caga by ihc staining in prospectively predicting the hp-dependence of gastric pure (de novo) dlbcl 4. the frequency of t(11;18)(q21;q21) translocation in gastric pure (de novo) dlbcl in taiwan. 5. the association between the cyp2c18/cyp2c19 genetic polymorphisms and eradication of hp infection after antibiotics.

the study will validate the use of antibiotics as first-line therapy for stage ie (and perhaps iie-1) hp-positive gastric pure (de novo) dlbcl. the status of nf-kb, bcl10, baff, and caga ihc nuclear staining will help to tailoring the treatment for early-stage gastric pure (de novo) dlbcl. and 50-60% of stage ie / iie-1 pure (de novo) dlbcl patients can be cured by 2-weeks of antibiotics rather than the 6-months of relatively toxic front-line systemic chemotherapy. the investigators shall also elucidate the distribution of cyp2c18/19 in patients with pure (de novo) dlbcl and their association with the efficacy of sequential antibiotics for eradication of hp infection.

Eligibility criteria:
inclusion criteria: 1. patients must have histologically confirmed h. pylori-positive primary gastric pure (de novo) gastric dlbcl. 2. patient must have no prior chemotherapy or radiotherapy for his/her gastric pure (de novo) gastric dlbcl. 3. patients must have evaluable disease by endoscopy and/or by computed tomography. 4. patients must have documented h. pylori infection before treatment, if any of the following test show positive result: histology, rapid urease test (clo-test), c13 urease breath test, and serology. 5. patients must have either stage ie or iie-1 disease, according to an adaptation of the ann arbor staging system modified by musshoff for primary extranodal lymphoma. 6. patients who are either newly diagnosed or already starting anti-h. pylori therapy but not have follow-up endoscopy and biopsy are eligible. 7. patient must have signed the informed consent, and agree to provide achieved pathologic material for immunohistochemical / fluorescence in situ hybridization study and rt-pcr for t(11;18)(q21;q21) determination. exclusion criteria: 1. patients with extensive gastrointestinal tract involvement. 2. patients with previous history of extranodal lymphoma. 3. patients with stage iie-2 or beyond disease: infiltration of regional lymph node. 4. patients with cardiopulmonary status that do not allow repeat endoscopy. 5. patients with prior chemotherapy or radiotherapy for their primary gastric lymphoma. 6. patients who had previous anti-h. pylori therapy and without pretreatment pathology achieve material for histological review and immunohistochemical study.

Keywords: helicobactor pylori, hp mucosa-associated lymphoid tissue-type lymphoma, maltoma
tofacitinib ointment for atopic dermatitis (atopic eczema)

Conditions: Dermatitis, Atopic

Summary: the study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) bid (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) bid for 4 weeks.


Eligibility criteria:
inclusion criteria: * have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at least 6 months prior to day 1 that has been clinically stable for at least 1 month prior to day 1 and is confirmed to be atopic dermatitis according to the criteria of hanifin and rajka. * have a pga score of 2 (mild) or 3 (moderate) at day 1. * have atopic dermatitis on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs including palms and soles covering at least 2% of total body surface area (bsa) and up to and including 20% of total bsa at day 1. at least 2% of the total bsa will need to be on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs (excluding palms and soles). exclusion criteria: * evidence of certain skin conditions/infections at baseline * currently have atopic dermatitis on groin, genitals, palm or soles * have certain laboratory abnormalities at baseline * females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception

Keywords: atopic dermatitis atopic eczema eczema topical treatment skin diseases tofacitinib cp-690 550 janus kinase inhibitor
state of obesity care in canada evaluation registry

Conditions: Obesity; Morbid Obesity

Summary: the purpose of this study is to see whether care gap(s) exist in the management of obesity and its related conditions in obese patients seen by primary care physicians and specialists. the study will also look at whether there is a compliance and adherence gap that exists in patients prescribed medication for obesity management.

obesity currently affects over 15% of the adult population in canada. the economic burden associated with obesity is estimated at $4.3 billion or 2.2% of the total health care costs in canada. despite increasing recognition as a public health problem, clinical management of obese patients in canada has received little attention. this study will collect information on the current status, characteristics and management of subjects with obesity. the design of the study will mirror real-life management of these subjects.there are three goals in this study: the primary goal is to document appropriate obesity management strategies aimed at reducing and maintaining a healthy body weight by participating primary care physicians and specialists. the second goal is to explore factors that determine patients compliance and adherence to anti-obesity medication when prescribed. obesity management is currently not a priority in tertiary care centres in canada. an exception being the bariatric clinic located at mcmaster university, which is one of the few academic centers dedicated to obesity management in canada. the primary goal of the bariatric clinic substudy is to evaluate the management, compliance and adherence of patients seen at a tertiary care obesity clinic compared to those of primary care physicians and specialists.

Eligibility criteria:
inclusion criteria: * age 18 years or older and is able to provide informed consent * has not been enrolled in this study at an earlier office visit; and * provides signed informed consent * bmi \> = 27 kg/m exclusion criteria: * participation in a clinical trial * hospitalized patient * subject expected to have difficulties to come back at follow-up visits * pregnant or nursing

Keywords: obesity weight gain anti-obesity medication anti-obesity management strategies body weight
rediscovering hydroxychloroquine as a novel insulin sensitizer

Conditions: Insulin Resistance

Summary: current options to treat insulin resistance in diabetes are fairly limited. for this reason, novel treatments would represent a major progress. the generic drug hydroxychloroquine (hcq) has poorly understood effects on blood sugar metabolism. in this study, the investigators will examine the mechanisms by which this drug affects glucose metabolism and which cells are affected. findings emanating from this project will help establish whether hcq may be a viable treatment for disorders of glucose metabolism.


Eligibility criteria:
inclusion criteria: * age 21-69 years-old; * bmi 28-40; * presence of at least one of the following markers of insulin resistance: a) fasting hyperinsulinemia (\>7 uu/ml by ultrasensitive insulin assay); impaired fasting glucose (100-125 mg/dl); prior history of impaired glucose tolerance provided by the participant; history of previous gestational diabetes; history of pcos; waist circumference \>40" (men) or \>35" (women) (cut-offs from atp-iii criteria for metabolic syndrome). exclusion criteria: * pregnancy, or unable/unwilling to avoid pregnancy during the study; * unstable cardiopulmonary disease, hepatitis, liver dysfunction, renal insufficiency, or any other medical condition affecting glucose metabolism or safety during the study; * diabetes; * medications that affect glucose metabolism: (e.g. systemic glucocorticoids, antipsychotics); * history of hypersensitivity to local lidocaine, similar anesthetics, or hcq; * history of g6pdh deficiency; * history of retinopathy; * weight instability (\>3kg of weight change in the past three months); * bariatric surgery in the last two years, intention to lose weight or engage in exercise regimen during study; * alcohol intake \>1 drink/day (averaged); * hemoglobin \<10g%
effect of intravenous lidocaine and dexamethasone combination on postoperative sore throat, cough and hoarseness.

Conditions: Postoperative Sore Throat, Cough, Hoarseness

Summary: post operative sore throat (post) following tracheal intubation is a common problem causing dissatisfaction and discomfort to the patients. prophylactic use of both lidocaine and dexamethasone has been used independently for this purpose. however, there is no study assessing the synergistic analgesic effects of lidocaine and dexamethasone for post. the purpose of this study is to compare the effect of lidocaine, dexamethasone and lidocaine dexamethasone combination on the incidence and severity of post.

sore throat and hoarseness following tracheal intubation are common postoperative problems causing dissatisfaction and discomfort to the patients. their incidence varies from 30%-70%. both non pharmacological and pharmacological measures have been tried to minimize the incidence and severity of post with variable success rate. prophylactic use lidocaine and steroids have been used independently for this purpose. dexamethasone as an adjuvant to lidocaine has shown to improve the quality of analgesia. however, there is no study assessing the combine effects of lidocaine and dexamethasone for post.

Eligibility criteria:
inclusion criteria: * patients of american society of anesthesiologist(asa) physical status 1 \& 2 requiring general anesthesia with endotracheal intubation. * duration of surgery more than 90 min exclusion criteria: * those with preexisting hoarseness or sorethroat * smoker * vocal performer by occupation * recent or recurrent respiratory tract infection * risk factors for postoperative aspiration * obesity * pregnancy * receiving analgesics, corticosteroids and calcium channel blockers * contraindication to corticosteroid medications * anticipated difficult intubation * mallampati grade \> 2 * difficult mask ventilation requiring oral or nasal airway * cormack and lehman grade iii and iv on laryngoscopy * more than one intubation attempt * those requiring orogastric or nasogastric tubes

Keywords: lidocaine, dexamethasone, postoperative sore throat